HeyJaredTraci L. Vitek
- Indexed articles, last 90 days
- 4
- Latest publication
- Sep 28, 2026
- Outlet visibility, for natlawreview.com
- Top 1M sites
- Earliest in this view
- Aug 5, 2026
Latest articles
The 340B Squeeze: Academic Medical Centers and Large Health Systems Have the Most to Lose (opens the original)
Read excerpt
Three federal pricing changes are about to land on a single outpatient claim. The largest infusion and oncology programs will feel them first, and hardest. Most of the 340B debate centers on rural hospitals and community health centers. The biggest dollars, however, sit with academic medical centers (AMCs) and large health systems, and that is where Washington's next three moves converge. In our August 17 analysis, 340B Rebates 2.0: HRSA Revives Its Pilot Program — and Sets Up a Collision Course
FemTech's Real Test- Can Innovation Solve Rural America's Maternal Health Crisis? (opens the original)
Read excerpt
"FemTech" is shorthand for a fast-growing category of technology built specifically for women's health. Once mostly period-tracking apps, it now spans regulated diagnostics, AI-driven risk prediction, and evidence-based therapeutics. In Women's Health at a Turning Point, we described federal policy finally catching up to that shift. That maturation matters well beyond investors and regulators. It is arriving just as the U.S. maternal health system faces collapse especially in rural and medically
340B Rebates 2.0- HRSA Revives Its Pilot Program — and Sets Up a Collision Course With Congress (opens the original)
Read excerpt
The Trump administration advances a claims-based rebate model for select 340B drugs as a new bipartisan Senate bill would block it, forcing health systems to track three reform paths at once. On July 31, 2026, the Health Resources and Services Administration (HRSA) announced a revised 340B Rebate Model Pilot Program, followed on August 3, 2026, by a formal Federal Register notice putting the details into effect. It is the agency's second attempt in just over a year to shift a subset of 340B drug
Women's Health at a Turning Point: What Federal Policy Changes Mean for the FemTech Industry (opens the original)
Read excerpt
For decades women's health has too often been treated as a narrow policy category, despite affecting roughly half the population. That is changing. There is now an emerging category of medicine built around regulated software, biomarker-based decision-making, and new regulatory and reimbursement pathways. FemTech now spans menstrual health, fertility, pregnancy and postpartum care, pelvic and sexual health, menopause, contraception, and conditions that affect women differently or disproportionat
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1M sites
For natlawreview.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.